人工智能在地图样萎缩临床管理中的应用:一个新型治疗领域需要新型工具
本文综述了继发于年龄相关性黄斑变性的地图样萎缩(GA)在首两种治疗药物获批后,诊断工具面临的挑战与人工智能(AI)的应用前景。文章描述了从传统到未来的GA分类与管理转变,指出基于OCT的AI方法可增强GA相关亚表型的识别与量化,FDA已将椭圆体带(EZ)衰减作为GA临床试验的主要结局指标。
要点
- 首两种GA治疗药物获批是重大突破,但缺乏治疗标准使诊断工具成为关键挑战。
- 多数解剖学生物标志物为亚临床,需先进敏感的影像分析,OCT可高分辨率显示光感受器等结构。
- FDA已将椭圆体带(EZ)衰减认定为GA临床试验的主要结局指标。
核心结论
- AI工具的出现使GA监测和筛查中的诊断与治疗概念发生了实质性变化。
- 新技术结合病理生理知识及对GA治疗反应的理解,正为自动化、高效和个体化患者护理开辟道路,具有改善及时治疗可及性和减少健康差异的巨大潜力。
研究设计与样本
- 本文为综述,描述了GA从过去到未来的分类与管理转变。
主要发现
- 首两种治疗地图样萎缩(GA)的药物获批是重大突破,此前众多试验均失败。
- GA的功能性参数难以提供,多数解剖学生物标志物为亚临床,需先进且敏感的影像分析。
- 与眼底自发荧光(FAF)相比,光学相干断层扫描(OCT)可高分辨率显示神经感觉层(包括光感受器)及其他超出人类专家评估范围的特征。
- 基于人工智能(AI)的方法强烈增强了临床相关GA亚表型的识别与量化。
- 引入基于OCT的生物标志物分析为疾病进展的病理机制和治疗提供了新见解,超越了传统描述性评估的局限。
关键数值与推荐
- FDA已将椭圆体带(EZ)衰减认定为GA临床试验的主要结局指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regulatory approval of the first two therapeutic substances for the management of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a major breakthrough following failure of numerous previous trials. However, in the absence of therapeutic standards, diagnostic tools are a key challenge as functional parameters in GA are hard to provide. The majority of anatomical biomarkers are subclinical, necessitating advanced and sensitive image analyses. In contrast to fundus autofluorescence (FAF), optical coherence tomography (OCT) provides high-resolution visualization of neurosensory layers, including photoreceptors, and other features that are beyond the scope of human expert assessment. Artificial intelligence (AI)-based methodology strongly enhances identification and quantification of clinically relevant GA-related sub-phenotypes. Introduction of OCT-based biomarker analysis provides novel insight into the pathomechanisms of disease progression and therapeutic, moving beyond the limitations of conventional descriptive assessment. Accordingly, the Food and Drug Administration (FDA) has provided a paradigm-shift in recognizing ellipsoid zone (EZ) attenuation as a primary outcome measure in GA clinical trials. In this review, the transition from previous to future GA classification and management is described. With the advent of AI tools, diagnostic and therapeutic concepts have changed substantially in monitoring and screening of GA disease. Novel technology combined with pathophysiological knowledge and understanding of the therapeutic response to GA treatments, is currently opening the path for an automated, efficient and individualized patient care with great potential to improve access to timely treatment and reduce health disparities.
引用
- Reiter GS, Mai J, Riedl S, et al. AI in the clinical management of GA: A novel therapeutic universe requires novel tools. Prog Retin Eye Res. 2024. PMID: 39343193. doi:10.1016/j.preteyeres.2024.101305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。